| NVYTF Stock | | | USD 0.63 0.02 3.28% |
Insider
James McCarthy is Acting CFO of Novacyt SA
| Age | 57 |
| Phone | 33 1 39 46 51 04 |
| Web | https://www.novacyt.com |
Novacyt SA Management Efficiency
The company has return on total asset
(ROA) of
0.0145 % which means that it generated a profit of $0.0145 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.0198) %, meaning that it generated substantial loss on money invested by shareholders. Novacyt SA's management efficiency ratios could be used to measure how well Novacyt SA manages its routine affairs as well as how well it operates its assets and liabilities.
Novacyt SA has accumulated 1.67
M in total debt with debt to equity ratio
(D/E) of 0.01, which may suggest the company is not taking enough advantage from borrowing. Novacyt SA has a current ratio of 4.57, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Novacyt SA until it has trouble settling it off, either with new capital or with free cash flow. So, Novacyt SA's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Novacyt SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Novacyt to invest in growth at high rates of return. When we think about Novacyt SA's use of debt, we should always consider it together with cash and equity.
Similar Executives
Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. The company was incorporated in 2006 and is based in Vlizy-Villacoublay, France. Novacyt operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 210 people. Novacyt SA [NVYTF] is a
Pink Sheet which is traded between brokers as part of OTC trading.
Management Performance
Novacyt SA Leadership Team
Elected by the shareholders, the Novacyt SA's board of directors comprises two types of representatives: Novacyt SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novacyt. The board's role is to monitor Novacyt SA's management team and ensure that shareholders' interests are well served. Novacyt SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novacyt SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
Novacyt Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Novacyt SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in Novacyt Pink Sheet
Novacyt SA financial ratios help investors to determine whether Novacyt Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Novacyt with respect to the benefits of owning Novacyt SA security.